Circadian Modulation in the Intestinal Absorption of P-Glycoprotein Substrates in Monkeys

Abstract

Recent studies in laboratory rodents have revealed that circadian oscillation in the physiologic functions affecting drug disposition underlies the dosing time-dependent change in pharmacokinetics. However, it is difficult to predict the circadian change in the drug pharmacokinetics in a diurnal human by using the data collected from nocturnal rodents. In this study, we used cynomolgus monkeys, diurnal active animals, to evaluate the relevance of intestinal expression of P-glycoprotein (P-gp) to the dosing time dependency of the pharmacokinetics of its substrates. The rhythmic phases of circadian gene expression in the suprachiasmatic nuclei (the mammalian circadian pacemaker) of cynomolgus monkeys were similar to those reported in nocturnal rodents. On the other hand, the expression of circadian clock genes in the intestinal epithelial cells of monkeys oscillated at opposite phases in rodents. The intestinal expression of P-gp in the small intestine of monkeys was also oscillated in a circadian time-dependent manner. Furthermore, the intestinal absorption of P-gp substrates (quinidine and etoposide) was substantially suppressed by administering the drugs at the times of day when P-gp levels were abundant. By contrast, there was no significant dosing time-dependent difference in the absorption of the non-P-gp substrate (acetaminophen). The oscillation in the intestinal expression of P-gp appears to affect the pharmacokinetics of its substrates. Identification of circadian factors affecting the drug disposition in laboratory monkeys may improve the predictive accuracy of pharmacokinetics in humans.

P-glycoprotein Function in the Rodent Brain Displays a Daily Rhythm, a Quantitative In Vivo PET Study

“…In contrast in rats, intestinal secretion of the P-gp substrates talinolol and losartan was greater during nocturnal activity (ZT13-ZT15) than daytime rest (ZT1-ZT3) (30). P-gp rhythm has been investigated also in daytimeactive cynomolgus monkeys (31). mRNA levels of Abcb1 oscillated in both the liver and intestine, but the daily variation was higher in the intestine being highest at ZT2 (early active phase) and lowest at ZT8 (mid-active phase).…”

P-glycoprotein multidrug transporter in inflammatory bowel diseases: More questions than answers

“…Circadian expression of p-gp in the intestine may functionally affect the pharmacokinetics of its substrates, leading to temporal changes in intestinal absorption and excretion[23]. Of note, changes in the expression of several circadian genes have also been observed in active IBD[24].…”

Some Aspects of Therapy of Bacterial Infections of Upper Respiratory Tract: What Remains Beyond Clinical Guidelines?

“…Другим примером могут служить респираторные фторхинолоны, которые не зависят от печеночного метаболизма, но для которых гликопротеин Р является субстратом. Так, наше соб-ственное исследование фармакокинетики респираторных фторхинолонов (левофлоксацина 500 мг) у пациентов с инфекцией дыхательных путей в комбинации с индуктора-ми гликопротеина Р (зверобоем продырявленным) показа-ло, что концентрация этого антибиотика достигала мини-мально допустимых значений (С max 4,1 ± 0,4 мкг/мл), что находит подтверждение в других исследованиях [53][54][55].…”